OR WAIT null SECS
February 24, 2016.
China will remain the largest major hepatitis B market over the next decade, rising from just under $923 million in 2014 to over $1.4 billion by 2024, according to research and consulting firm GlobalData. This represents a rise in market share from 38.8% to 47.2%.
GlobalData analyst Daian Cheng, Ph.D., said: “China’s proportion of treated cases is much higher than its market share because hepatitis B therapeutics cost much less compared with other regions. Indeed, it is the sheer increase in the number of drug-treated patients that will drive market growth.
“The projected increase of patients alone, nearly 300,000 between 2014 and 2024, is much more than the total number of treated patients in the US, which is around 100,000. Thus, the increase in therapeutic sales will be considerable and China will hang on to its market dominance, even with lower drug prices.”